DE60130976D1 - Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs - Google Patents

Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs

Info

Publication number
DE60130976D1
DE60130976D1 DE60130976T DE60130976T DE60130976D1 DE 60130976 D1 DE60130976 D1 DE 60130976D1 DE 60130976 T DE60130976 T DE 60130976T DE 60130976 T DE60130976 T DE 60130976T DE 60130976 D1 DE60130976 D1 DE 60130976D1
Authority
DE
Germany
Prior art keywords
treatment
cancer
protein transferase
transferase inhibitors
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130976T
Other languages
English (en)
Other versions
DE60130976T2 (de
Inventor
David William End
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60130976D1 publication Critical patent/DE60130976D1/de
Application granted granted Critical
Publication of DE60130976T2 publication Critical patent/DE60130976T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60130976T 2000-02-24 2001-02-20 Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs Expired - Lifetime DE60130976T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18455100P 2000-02-24 2000-02-24
US184551P 2000-02-24
PCT/EP2001/001937 WO2001062234A2 (en) 2000-02-24 2001-02-20 Dosing regimen

Publications (2)

Publication Number Publication Date
DE60130976D1 true DE60130976D1 (de) 2007-11-29
DE60130976T2 DE60130976T2 (de) 2008-07-17

Family

ID=22677368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130976T Expired - Lifetime DE60130976T2 (de) 2000-02-24 2001-02-20 Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs

Country Status (9)

Country Link
US (1) US6838467B2 (de)
EP (1) EP1267848B1 (de)
JP (1) JP2003523381A (de)
AT (1) ATE375794T1 (de)
AU (1) AU2001231763A1 (de)
CA (1) CA2397558A1 (de)
DE (1) DE60130976T2 (de)
ES (1) ES2293972T3 (de)
WO (1) WO2001062234A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60118889T2 (de) * 2000-02-04 2006-11-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US20040110769A1 (en) * 2001-02-15 2004-06-10 End David William Farnesyl protein transferase inhibitor combinations with antiestrogen agents
AU2002352941A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
KR101150172B1 (ko) * 2004-01-23 2012-05-25 얀센 파마슈티카 엔.브이. 치환된 퀴놀린 및 마이코박테리아 저해제로서의 용도
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1732549A4 (de) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP2545919A1 (de) 2005-12-23 2013-01-16 Link Medicine Corporation Behandlung von Synucleinopathien
JP2010507662A (ja) * 2006-10-25 2010-03-11 シェーリング コーポレイション 癌の処置のための不連続方法
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) * 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EA201590750A1 (ru) 2012-10-16 2015-09-30 Янссен Фармацевтика Нв СВЯЗАННЫЕ С ФЕНИЛОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγT
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
WO2015057629A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP3534885B1 (de) 2016-11-03 2021-01-20 Kura Oncology, Inc. Farnesyltransferase-inhibitoren zur verwendung bei der behandlung von krebs
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN114796218A (zh) 2017-02-21 2022-07-29 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
KR20200051601A (ko) 2017-08-07 2020-05-13 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
SG11202104296TA (en) 2018-11-01 2021-05-28 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
WO2020132437A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5834434A (en) * 1993-05-18 1998-11-10 University Of Pittsburgh Inhibitors of farnesyltransferase
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CN1095845C (zh) 1996-12-20 2002-12-11 "塔比法尔"有限责任公司 制取冻干的1β,10β－环氧－13－二甲基氨基－愈创－3(4)－烯－6,12－内酯盐酸盐的方法和装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
AU4925199A (en) 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
CN1314904A (zh) 1998-08-27 2001-09-26 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉－2－酮衍生物
IL143859A0 (en) 1998-12-23 2002-04-21 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives

Also Published As

Publication number Publication date
EP1267848A1 (de) 2003-01-02
ATE375794T1 (de) 2007-11-15
WO2001062234A2 (en) 2001-08-30
CA2397558A1 (en) 2001-08-30
DE60130976T2 (de) 2008-07-17
US6838467B2 (en) 2005-01-04
US20030060450A1 (en) 2003-03-27
EP1267848B1 (de) 2007-10-17
ES2293972T3 (es) 2008-04-01
JP2003523381A (ja) 2003-08-05
WO2001062234A8 (en) 2001-09-27
AU2001231763A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
DE60130976D1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60219595D1 (de) Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
DE69912790D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
MY151032A (en) Treatment of tnf? related disorders
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
ATE276753T1 (de) Verfahren zur hemmung der krebsmetastasierung durch orale verabreichung von löslichem modifiziertem zitruspektin
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE382346T1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE443044T1 (de) Tace inhibitoren
ATE439130T1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
NO20024755D0 (no) Metode
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition